Stock DNA
Pharmaceuticals & Biotechnology
PKR 122,537 Million (Large Cap)
15.00
NA
3.90%
-0.24
30.90%
4.12
Revenue and Profits:
Net Sales:
15,580 Million
(Quarterly Results - Mar 2025)
Net Profit:
2,127 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.23%
0%
-2.23%
6 Months
0.96%
0%
0.96%
1 Year
193.62%
0%
193.62%
2 Years
382.87%
0%
382.87%
3 Years
215.27%
0%
215.27%
4 Years
131.41%
0%
131.41%
5 Years
110.72%
0%
110.72%
GlaxoSmithKline Pakistan Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.70%
EBIT Growth (5y)
30.01%
EBIT to Interest (avg)
15.50
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.20
Sales to Capital Employed (avg)
2.23
Tax Ratio
37.88%
Dividend Payout Ratio
48.72%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
25.87%
ROE (avg)
16.75%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
4.68
EV to EBIT
9.57
EV to EBITDA
8.78
EV to Capital Employed
5.73
EV to Sales
2.08
PEG Ratio
0.06
Dividend Yield
3.49%
ROCE (Latest)
59.85%
ROE (Latest)
30.99%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
15,580.10
17,585.60
-11.40%
Operating Profit (PBDIT) excl Other Income
4,063.10
4,282.30
-5.12%
Interest
114.10
71.00
60.70%
Exceptional Items
0.00
0.00
Consolidate Net Profit
2,126.50
2,954.80
-28.03%
Operating Profit Margin (Excl OI)
240.30%
226.70%
1.36%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is -11.40% vs 19.38% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is -28.03% vs 53.33% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
61,187.50
49,661.30
23.21%
Operating Profit (PBDIT) excl Other Income
9,204.10
-2,371.50
488.11%
Interest
91.70
63.00
45.56%
Exceptional Items
-24.00
-152.70
84.28%
Consolidate Net Profit
6,536.00
534.00
1,123.97%
Operating Profit Margin (Excl OI)
131.90%
-66.50%
19.84%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 23.21% vs 18.69% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 1,123.97% vs -78.32% in Dec 2023
About GlaxoSmithKline Pakistan Ltd. 
GlaxoSmithKline Pakistan Ltd.
Pharmaceuticals & Biotechnology
GlaxoSmithKline Pakistan Limited is a Pakistan-based pharmaceutical company. The Company is engaged in manufacturing and marketing of research based ethical specialties, other pharmaceutical and consumer products. The Company operates through two segments: Pharmaceuticals and consumer healthcare. The Company's Pharmaceuticals segment includes prescription drugs and vaccines. The Company's consumer healthcare segment includes over-the-counter-medicines, oral care and nutritional care. In Pakistan, the Company deals in anti-infective, respiratory, vaccines, dermatological, analgesics, oncology, urology, central nervous system, allergy, cardiovascular and vitamins therapy areas. The Company's pharmaceutical brands include Augmentin, Seretide, Amoxil, Velosef, Zantac and Calpol, and consumer healthcare brands, which include Panadol, Horlicks, Sensodyne and ENO. Its vaccines include Synflorix, Infanrix Hexa, Rotarix, Havrix and Priorix Tetra.
Company Coordinates 
Company Details
Sykes Building, 35-Dockyard Road, West Wharf KARACHI None : 74000
Registrar Details






